Eli Lilly and Company, Gilead Sciences, Thermo Fisher Scientific, Merck & Co., Inc., and Abbott Laboratories are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies engaged in the research, development, manufacturing and marketing of prescription and over-the-counter medications. Their performance is often driven by factors such as clinical trial results, regulatory approvals, patent expirations and broader healthcare trends, offering investors both growth potential and volatility. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Eli Lilly and Company stock traded down $15.02 during trading hours on Friday, hitting $780.10. 1,617,041 shares of the stock were exchanged, compared to its average volume of 3,665,851. The stock has a market capitalization of $739.33 billion, a P/E ratio of 63.50, a P/E/G ratio of 1.16 and a beta of 0.40. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The business's 50-day moving average is $781.50 and its two-hundred day moving average is $800.11. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53.
Read Our Latest Research Report on LLY
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Shares of GILD traded up $2.93 during trading hours on Friday, reaching $110.55. The stock had a trading volume of 6,365,083 shares, compared to its average volume of 7,635,926. Gilead Sciences has a 52 week low of $66.01 and a 52 week high of $119.96. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. The company has a market cap of $137.51 billion, a P/E ratio of 23.21, a P/E/G ratio of 0.69 and a beta of 0.29. The firm has a 50-day moving average of $106.27 and a 200 day moving average of $103.15.
Read Our Latest Research Report on GILD
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
TMO stock traded down $1.38 during trading hours on Friday, reaching $410.74. The stock had a trading volume of 1,554,794 shares, compared to its average volume of 1,957,735. The stock has a 50-day simple moving average of $410.11 and a 200 day simple moving average of $484.47. The stock has a market capitalization of $155.05 billion, a PE ratio of 24.09, a price-to-earnings-growth ratio of 2.17 and a beta of 0.78. Thermo Fisher Scientific has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38.
Read Our Latest Research Report on TMO
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Shares of MRK stock traded down $0.35 during mid-day trading on Friday, reaching $78.48. 6,612,533 shares of the stock traded hands, compared to its average volume of 13,113,752. The company has a market cap of $197.07 billion, a price-to-earnings ratio of 11.42, a price-to-earnings-growth ratio of 0.83 and a beta of 0.38. The stock's fifty day simple moving average is $79.04 and its two-hundred day simple moving average is $87.88. The company has a quick ratio of 1.16, a current ratio of 1.41 and a debt-to-equity ratio of 0.69. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $132.29.
Read Our Latest Research Report on MRK
Abbott Laboratories (ABT)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Shares of Abbott Laboratories stock traded up $0.39 during trading hours on Friday, reaching $134.06. The company's stock had a trading volume of 3,653,889 shares, compared to its average volume of 6,127,383. The company has a market capitalization of $233.25 billion, a P/E ratio of 17.40, a P/E/G ratio of 2.61 and a beta of 0.73. Abbott Laboratories has a one year low of $99.71 and a one year high of $141.23. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.27 and a current ratio of 1.78. The stock's fifty day simple moving average is $132.75 and its two-hundred day simple moving average is $127.43.
Read Our Latest Research Report on ABT
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
